The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

— Working with Stago management, ARCHIMED aims to expand sales and profits by building on gold-standard products in both developed and developing nations MONTRÉAL, April 29, 2026 /CNW/ - ARCHIMED ...

May 1 (Reuters) - Investment firm Archimed will take Esperion Therapeutics private for up to $1.1 billion, the companies said on Friday, sending the drugmaker's shares up over 55% in premarket trading ...

ArchiMed has acquired Zyto, a German provider of cancer diagnostics. No financial terms were disclosed. ArchiMed buys Germany’s Zyto Group of Cancer Diagnostics companies in partnership with owners ...

Esperion Therapeutics ESPR shares are up during Friday’s premarket session as the company has announced a definitive agreement to be acquired by ARCHIMED. The deal will provide Esperion shareholders ...

February 12, 2018 – Benoît Adelus and André-Michel Ballester are joining the senior management of European private equity healthcare specialist ArchiMed, expanding the firm’s number of partners from ...

Shortly after laying out $75 million upfront for Corstasis Therapeutics and its congestive heart failure edema drug Enbumyst, Esperion Therapeutics is itself being acquired and taken private by ...

The three-year-old spinout from Zimmer Biomet has reached the end of its road. ZimVie has agreed to be acquired by the investment firm ArchiMed, through a $730 million deal that aims to close before ...

Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments Represents total equity value of up ...

ANN ARBOR, Mich., May 01, 2026 (GLOBE NEWSWIRE)-- Esperion Therapeutics (Nasdaq: ESPR) (“Esperion,” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and ...